Submitted by: Bayer
Posted: Apr 13, 2020 – 08:00 PM EST
LEVERKUSEN, Germany, Apr. 13 /CSRwire/ - Bayer is supporting the fight against the corona pandemic in Spain with a comprehensive aid package. The company is donating 800,000 euros to the national health system in Spain for the purchase of urgently needed medical equipment and hospital beds.
Further contributions of more than 100.000 euros include the donation of test equipment for the diagnosis of Covid-19 to one of the research centers of Consejo Superior de Investigaciones Científicas (CSIC), a prestiogious public research institution, as well as support for the “Coronavirus Emergency in Spain" program of the Red Cross.
In addition, a network of Bayer employees including doctors, biologists, pharmacists and psychologists has come together to volunteer their expertise. They offer their assistance either through telemedicine programs or directly at health facilities. Bayer is actively supporting these efforts by employees through paid leaves of absence. For teachers, the company offers an information service developed in cooperation with science organizations that supplies them with coronavirus related materials and learning aids for online teaching.
The Spanish aid package is one of numerous bundles of measures with which Bayer is commited to fight against the corona pandemic worldwide with its products, technical equipment, know-how and the engagement of its employees. You can find a current overview here: https://www.bayer.com/en/coronavirus-covid-19-update.aspx .
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For more information, please contact:There is currently no contact information.
For more from this organization:Bayer